Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition

Roche Holding RHHBY has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc. ONCE, the companies announced Tuesday. 

The regulatory authorities concluded the deal would not hurt competition in hemophilia A treatment. 

Reuters reports the takeover is estimated at $4.3 billion; Roche has agreed to pay more than twice the U.S. company’s closing price on Feb. 22. As of Tuesday, Roche holds more than 60% of Spark shares.

Roche said it intends to complete the acquisition of Spark Tuesday through a merger of 022019 Merger Subsidiary, Inc.

Once the merger has been completed, Spark will become a wholly owned subsidiary of Roche, with Spark shares ceasing to trade on the Nasdaq exchange.

Roche Holding shares were trading down 0.1% at $38.57 in Tuesday’s premarket session. The stock has a 52-week high of $38.87 and a 52-week low of $25.10.

Spark Therapeutics shares were trading up 0.8% at $114.48 in the premarket session. The stock has a 52-week high of $114.20 and a 52-week low of $34.53.

Related Links:

The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

The Gene Therapy Names Moving On The Audentes Buyout Deal

Posted In: gene therapyReutersBiotechM&ANewsGeneral